Why does native tissue pharmacology matter? Native tissue preserves physiological receptor density, multi-receptor co-expression, endogenous signalling stoichiometry, and post-translational modifications. Compounds profiled in endogenous systems deliver data that translates more reliably to in vivo efficacy and clinical outcomes.

Drug discovery often starts with reductionist models: one receptor, one cell line, one readout. Recombinant systems offer reproducibility and throughput, and they are useful for primary screening. But they are still an abstraction. In the body, receptors sit alongside other receptor types, ion channels, enzymes, and signalling scaffolds. A compound can behave very differently in that endogenous context; often, that is where the real pharmacology becomes clear.

This is why I am wary of making final pharmacology decisions from CHO or HEK data alone. They are useful systems, but they are not the tissue.

The Problem with Overexpression

A CHO cell line stably expressing a GPCR may present receptor densities far above those found in many native tissues, where receptor expression is often lower and more regionally heterogeneous. That extra receptor reserve has direct pharmacological consequences. Partial agonists can appear as full agonists because receptor reserve masks their lower intrinsic efficacy. Potency values can shift left. The rank order of compound efficacy can also change when moving from high expression systems to endogenous tissue. These are not small differences. They can redirect medicinal chemistry and mislead dose prediction.

Multi-Receptor Expression: The Tissue as Pharmacological Context

A single brain region such as the dorsal raphe contains 5-HT_1A autoreceptors, GABA_A receptors, adrenergic receptors, glutamate receptors, and inputs from other receptor systems simultaneously. A drug acting at one target does so in the presence of tonic endogenous activity at all the others. Cross-talk, allosteric modulation, and signalling convergence mean the net pharmacological effect is an emergent property of this multi-receptor environment.

Atypical antipsychotics derive their clinical profile from a combination of D₂ antagonism, 5-HT_2A antagonism, and variable activity at histamine, muscarinic, and adrenergic receptors. The therapeutic window depends on the interaction of these activities, not D₂ affinity alone.

Biased Agonism in Endogenous Systems

A compound showing G protein bias in a recombinant system may show a different bias profile, or no bias at all, in native tissue where G protein, arrestin, and GRK stoichiometry reflects physiological reality. This is why bias translation from recombinant to native systems remains such a difficult problem in receptor pharmacology.

Receptor Co-Expression Changes Pharmacology

Multi-receptor expression matters beyond simple signalling cross-talk. Co-expression of receptor subtypes in the same cell can lead to heterodimer formation, altering binding pharmacology, G protein coupling, and trafficking. We demonstrated this in our own MOP-NOP receptor co-expression studies (Bird et al., 2022), where co-expression of mu opioid (MOP) and nociceptin (NOP) receptors in HEK cells produced bidirectional displacement of radioligands that did not occur in single expression systems. N/OFQ displaced [³H]DPN binding, and Dermorphin displaced [³H]N/OFQ binding; effects only observed when both receptors were present. In [³⁵S]GTPγS and cAMP assays, NOP activation shifted the MOP concentration-response curve rightward. These interactions were probed further with fluorescent ligands: in HEKMOP/NOP cells, Dermorphin-Alexa488 and N/OFQ-Alexa594 colocalised and FRET confirmed close receptor proximity, while in mouse CA1 hippocampal slices the same fluorescent ligand pair colocalised with binding selectively reversed by CTOP for MOP and SB-612111 for NOP. This supports receptor co-expression in native tissue, while keeping the FRET evidence correctly assigned to the HEK co-expression model.

This type of receptor-receptor interaction is invisible in single-target recombinant screens. It is only detectable in systems where both receptors are present at relevant densities, either in co-expression systems with matched receptor levels or in native tissue. The pharmacological consequence is real. Mixed MOP-NOP agonists such as cebranopadol produce analgesia with reduced side effects, a profile that depends on the interaction between these receptor systems.

Off-Target Selectivity and Species Translation

A compound appearing clean across a recombinant receptor panel may show unexpected binding in tissue, where receptors are expressed at physiological levels alongside endogenous competitors. Autoradiography across brain, heart, lung, gut, and kidney identifies off-target liabilities before they become clinical surprises.

Species translation requires parallel binding studies on rodent and human tissue preparations. Receptor density, splice variant expression, and tissue distribution differ between species; relying exclusively on rodent recombinant data risks pharmacological surprises in the clinic.

Tools for Endogenous Pharmacology

Radioligand binding on native tissue provides affinity data at physiological receptor density. Autoradiography maps spatial distribution. [³⁵S]GTPγS functional assays with G protein subtype-selective immunocapture (G_s, G_q, G_i/o) measure receptor-effector coupling in native membranes. Calcium and cAMP assays in primary cells reflect endogenous receptor-effector stoichiometry. Neurotransmitter uptake and release assays on synaptosomes assess presynaptic function in authentic transporter context.

Gifford Bioscience: Built on Endogenous Tissue Pharmacology

At Gifford Bioscience, endogenous tissue pharmacology is central to how we work. We work with rodent, non-human primate, and ethically sourced human tissue to deliver binding, functional, and spatial data that recombinant systems cannot replicate. A single programme can move from target affinity through functional profiling to tissue-level engagement, all within endogenous receptor and signalling environments. That is where specialist receptor pharmacology adds real value.

To discuss how Gifford Bioscience can support your programme, visit www.giffordbioscience.com or contact us at info@giffordbioscience.com.

Frequently Asked Questions

What is endogenous tissue pharmacology?

Endogenous tissue pharmacology studies receptors and signalling pathways within native biological tissues where they are expressed naturally. Unlike recombinant cell systems, native tissue preserves physiological receptor density, receptor co-expression, signalling proteins and other cellular components that can influence a compound’s pharmacology.

Why can drug responses differ between recombinant cells and native tissue?

Recombinant systems such as CHO or HEK cells can express receptors at much higher densities than occur physiologically. This may create receptor reserve, alter apparent potency and efficacy, and cause partial agonists to behave differently. Native tissue provides a more physiologically relevant environment for understanding how a compound is likely to behave in vivo.

Why is multi-receptor expression important in drug discovery?

Receptors rarely operate in isolation in biological tissues. Multiple receptor subtypes, ion channels, transporters and signalling pathways can be expressed within the same cells or tissue regions. Interactions between these systems can alter receptor signalling, ligand binding and functional responses, revealing pharmacology that may not be apparent in single-target recombinant assays.

Can endogenous tissue help assess biased agonism?

Biased agonism can depend on the relative abundance of G proteins, arrestins, GRKs and other signalling proteins. Because these components occur at physiological levels in native tissue, endogenous systems can help determine whether signalling bias observed in recombinant assays translates into a biologically relevant environment.

Which assays can be used to study receptor pharmacology in native tissue?

Several techniques can be applied to endogenous systems, including radioligand binding assays, receptor autoradiography, [35S]GTPγS functional assays, calcium and cAMP assays in primary cells, and neurotransmitter uptake or release assays. Used together, these approaches can provide complementary information on receptor affinity, distribution, signalling and functional activity.

References

Kenakin T. The relative contribution of affinity and efficacy to agonist activity. Br J Pharmacol. 1984;81(1):131-141.
Kenakin T. New concepts in pharmacological efficacy at 7TM receptors: IUPHAR Review 2. Br J Pharmacol. 2013;168:554-575. doi:10.1111/j.1476-5381.2012.02223.x.
Kenakin T. Bias translation: the final frontier? Br J Pharmacol. 2024;181(9):1345-1360. doi:10.1111/bph.16335.
Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507-519.
Moffat JG, et al. Opportunities and challenges in phenotypic drug discovery. Nat Rev Drug Discov. 2017;16(8):531-543.
Kenakin TP, et al. A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci. 2012;3(3):193-203.
Manuel I, et al. Neurotransmitter receptor localisation: from autoradiography to imaging mass spectrometry. ACS Chem Neurosci. 2015;6(3):362-373.
Bird MF, et al. MOP and NOP receptor interaction: Studies with a dual expression system and bivalent peptide ligands. PLoS ONE. 2022;17(1):e0260880.

The Endogenous Tissue Advantage: Why Multi-Receptor Expression in Native Systems Matters for Drug Discovery